NDANASALSPRAY, METERED2 Generics Approved
Approved
Dec 1997
Lifecycle
LOE Approaching
Competitive Pressure
60/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 22h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MIGRANAL is a metered nasal spray formulation of dihydroergotamine mesylate, an ergot-derived vasoconstrictor approved for acute migraine treatment. It provides rapid intranasal delivery to abort migraine attacks without requiring IV administration. The drug works by constricting intracranial blood vessels and modulating serotonin signaling pathways.
$0.552MPart D
LOE ApproachingWith LOE approaching and minimal Part D spending ($552K), this product faces declining commercial relevance and likely smaller team size or consolidation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure
Started Mar 2010
24 enrolled
Healthy
Career Relevance
Working on MIGRANAL offers limited career growth potential given its mature, declining lifecycle and minimal current job openings (0 linked positions). This role is best suited for professionals seeking stability in a niche market or those interested in managing legacy products during generic transition.
Brand Manager
Worked on MIGRANAL at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.